Revenue for the quarter ended March 31, 2026, was $22,842, a 99% decrease compared to $2,137,075 in the same period of 2025. Net loss for the quarter was $543,575, compared to a net loss of $623,327 in the prior year period. Cash and cash equivalents stood at $2,397,977 as of March 31, 2026. The company is transitioning its Chemrex subsidiary from industrial chemical trading to a CDMO model. Management issued Letters of Demand to five former officers and directors seeking recovery of approximately $2.94 million for unauthorized transactions.